Oncolytics Biotech Inc.
December 31, 2005 and 2004
STATEMENT OF MANAGEMENT’S RESPONSIBILITY
Management is responsible for the preparation and presentation of the financial statements, Management’s Discussion and
Analysis (“MD&A”) and all other information in the Annual Report.
In management’s opinion, the accompanying financial statements have been properly prepared with reasonable limits of
materiality and within the appropriately selected Canadian generally accepted accounting principles and policies consistently
applied and summarized in the financial statements.
The MD&A has been prepared in accordance with the requirements of securities regulators as applicable to Oncolytics Biotech
The financial statements and information in the MD&A generally include estimates that are necessary when transactions
affecting the current accounting period cannot be finalized with certainty until future periods. Based on careful judgments by
management, such estimates have been properly reflected in the accompanying financial statements and MD&A. The MD&A
also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources and
risks and uncertainty. Actual results in the future may differ materially from our present assessment of this information because
future events and circumstances may not occur as expected.
Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting,
assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide
reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for financial
We, as the Chief Executive Officer and Chief Financial Officer will certify to the our annual filings with the CSA and the SEC as
required in Canada by Multilateral Instrument 52-109 (certification of Disclosure in Iss